Background: EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is not readily available to the scientific community.
Background
According to Global Health Council despite advances in the understanding of cancer biology, malignant neoplasms remain the second leading cause of mortality in United States. Novel therapies are needed and over the past two decades new immunotherapy strategies have emerged as a promising approach. The success of these immunotherapeutic strategies is highly dependent on finding an ideal antigen to target. One such target is the EGF receptor which is over or aberrantly expressed in a variety of human cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . However, the fact that the EGF receptor is present on normal tissue could lead to possible deleterious side effects or immune tolerance when treating patients with reagents solely targeting the EGF receptor. A tumor specific antigen would be more ideal. Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF receptor and is expressed in a number of solid tumors including glioblastoma multiforme (GBM), breast adenocarcinoma, medulloblastoma and ovarian adenocarcinoma, but has only rarely been observed in normal tissue [13] [14] [15] . This variant receptor results from an inframe deletion of exons 2-7 of the wild type EGF receptor. This causes a deletion of a large portion of the extracellular domain and the generation of a novel glycine at the fusion junction between exon 1 and exon 8 [16] [17] [18] . EGFRvIII is ligand independent yet constitutively active and when expressed in cells it leads to unregulated growth, survival, invasion, and angiogenesis [19] . EGFRvIII is an ideal target for immunotherapy because the juxtaposition of exon 1 and 8 sequences plus the novel glycine creates a highly immunogenic tumor specific antigen, and the receptor itself leads to a cancer phenotype due to its constitutive activity [1, [20] [21] [22] .
There are a number of immune approaches that specifically target EGFRvIII. For example, a peptide vaccine targeting this mutant receptor is currently being tested in clinical trials for GBM patients [23, 24] . Another approach is the development of antibodies that recognize EGFRvIII which can be used for diagnostic/laboratory purposes or for therapeutic purposes either alone or attached to a cytotoxic or radiolabeled adjunct [25, 26] . Many of the monoclonal antibodies that target EGFRvIII, however, have cross reactivity with the wild type EGF receptor or other non-specific proteins [27] or comparatively have low affinity. While polyclonal antibodies are apparently highly sensitive and of high affinity, it is difficult to produce them in mass quantities. An additional complicating factor is that the rights to the antibody for EGFRvIII are patented and have not been made widely available for either scientific or medical use.
To generate a highly specific and cost effective antibody that could be used for scientific and clinical purposes, we developed a recombinant antibody. Recombinant antibody technology has gained popularity in recent years because of its many advantages when compared with the production of monoclonal or polyclonal antibodies. First, no animals are needed and the manufacturing time is relatively short compared with conventional methods. Moreover, the quality and quantity of the final product is superior when compared to conventional antibody production. Recombinant antibodies are formed by combining single-chain Fv antibodies, consisting of V H and V L chains, by a flexible linker [28] . In this report, we describe how we created a recombinant antibody that specifically recognizes EGFRvIII and demonstrate its specificity by western blot analysis, immunohistochemistry (IHC), immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA) and flow cytometry analysis (FACS). This easily produced and highly specific recombinant antibody holds great potential to be used as a diagnostic and a therapeutic tool.
Results

Western Analysis
We constructed the first recombinant EGFRvIII antibody, RAb vIII , using the sequence of MR1-1, an scFv developed against EGFRvIII (Figure 1 ) [29] . To determine the specificity of RAb vIII antibody for EGFRvIII, we used it for western blot analysis. Consistent with previously published data, the RAb vIII antibody recognizes the 145 kDa EGFRvIII protein band in U87-vIII cells stably expressing EGFRvIII (U87-vIII) compared to the U87-MG untransfected cells (Figure 2A ) [30] . The RAb vIII antibody also faintly recognized the endogenous 170 kDa wild type EGF receptor and it strongly recognize a 45 kDa protein band in both U87-vIII and U87-MG control cells. We speculated that the 45 kDa protein was cross-reaction with another EGF receptor variant that we have recently identified, called mLEEK. MiniLEEK (mLEEK) is the result of the fusion of exon 1 to exon 23 and is predicted to be 45 kDa in size (Piccione et al., submitted). This also creates a glycine at the junction and the fusion junction (LEEKKGVTVWEL) bears some resemblance to the EGFRvIII sequence.
The crystal structure of MR1-1 in complex with the EGFRvIII peptide has been done by Landry et al. [31] This shows the valine at P9 position of the EGFRvIII peptide forms a hydrogen bond with tyrosine at H59 and H105 on MR1-1. The mLEEK peptide has a valine at the identical position. Since RAb vIII potentially cross reacted with mLEEK, to eliminate the non-specific 45 kDa band we mutated the tyrosines at H59 and H105 to phenylalanine.
To determine if the mutated RAb DMvIII has improved specificity towards EGFRvIII, we conducted another western analysis. We found that RAb DMvIII now specifically recognizes only the EGFRvIII 145 kDa protein band and not the EGFR variant 45 kDa band (Figure 2A) . We also more rigorously tested cross-reaction with wt EGF receptor by performing Western blots using lysates from A431 cells, which express 1 × 10 6 receptors per cell. When we studied the specificity of RAb DMvIII towards the overexpressed wild type EGFR present in A431 cells we discovered that the RAb DMvIII antibody did cross-react with the 170 kDa wild type protein ( Figure 2B) .
Consequently, to further study the specificity of the RAb DMvIII under these conditions we expanded our analysis to include HC2 cells which expresses EGFRvIII at a level comparable to that of EGFR expressed by A431 ( Figure 2B ). Western analysis using anti-EGFR antibody E3138 from Sigma shows that there are similar amounts of wild type EGFR and EGFRvIII protein expressed in A431 and HC2 cells ( Figure 2B ).
Based on the study done by Johns et al. which showed that monoclonal antibody 806 recognizes overexpressed EGFR in A431 cells only under reducing conditions, we further analyzed both HC2 and A431 cell lysates under non-reducing western conditions [32] . Western analysis under these conditions shows that recombinant RAb DMvIII recognizes only the EGFRvIII 145 kDa band and not the wild type EGFR 170 kDa band ( Figure 2C ) suggesting that under reducing conditions the EGFR epitope is somewhat more exposed and accessible to RAb DMvIII [32] . On the other hand, the non mutated RAb vIII consistently recognizes the 170 kDa wild type EGFR band even under nonreducing western conditions clearly illustrating that RAb DMvIII is a more specific EGFRvIII antibody than RAb vIII .
Antibody Affinity
To determine the affinity constant of the antibody, we used the method described by Friguet et al. (1984) [33] . It is necessary that the concentration of the antibody used in the ELISA should be equal to or less than the value of dissociation constant of the antibody. Thus a preliminary ELISA was performed to deduce the dissociation constant of the antibody. From the preliminary ELISA, the dissociation constant of RAb vIII and RAb DMvIII is calculated to be approximately 1.7 μM and 886 nM, respectively, against EGFRvIII peptide ( Figure 3A ). This result suggests that RAb DMvIII did not lose its affinity after mutation as RAb DMvIII has a lower dissociation constant than RAb vIII . The indirect ELISA was performed with RAb DMvIII using a concentration of 117 nM, which is lower than its dissociation constant value of 886 nM. The OD values from this ELISA were placed in a Scatchard plot equation where the fraction of bound antibody sites α (determined from the OD values) is plotted on the X axis and the ratio of the fraction of bound antibody sites α to free antigen sites c, (α/c) is plotted on the Y axis. The slope gives the value of -K, the affinity constant of the antibody, which is 1.7 × 10 7 M -1 ( Figure 3B ).
Immunoprecipitation
Immunoprecipitation of HC2 and A431 cell lysates was performed using RAb DMvIII and G100 an anti-EGFRvIII monoclonal antibody (no longer commercially available). As a negative recombinant antibody control for EGFR wt and EGFRvIII, we also used RAb CD133 , which utilizes the same expression vector as RAb DMvIII but is directed against CD133 and recognizes neither EGFR wt nor EGFRvIII. HC2 cell lysates immunoprecipitated with RAb DMvIII and G100 antibody and then further immunoblotted with E3138 antibody showed the expected 145 kDa band corresponding to EGFRvIII in the pellet whereas RAb CD133 did not show the 145 kDa band in the pellet as it does not bind to EGFRvIII ( Figure 4A ) On the contrary, when A431 cell lysates were immunoprecipitated with either RAb DMvIII , G100 or RAb
CD133
and then immunoblotted with the E3138 antibody, the170 kDa bands corresponding to wt EGFR was found in the supernatant ( Figure 4B ). This suggested that even when abundant amounts of wt EGFR protein is present RAb DMvIII did not bind to any wild type EGFR.
Immunofluorescence
Since the specificity of RAb DMvIII is greatly enhanced under native conditions, we decided to test the recombinant antibody specificity under in vivo conditions. To this end, indirect immunofluorescence was performed on HC2 and A431 cells with RAb DMvIII at a concentration of 0.25 μg/μl. Images were taken using a Leica SP2 AOBS confocal microscope. Consistent with previous findings, the RAb DMvIII shows that the EGFRvIII protein is both membrane bound and has an intracellular localization ( Figure 5A ) [1, 6, 34] . To verify the specificity of the RAb DMvIII antibody we conducted a peptide competition using the EGFRvIII epitope (LEEKKGNYVVTDHC). The presence of the EGFRvIII epitope completely blocked RAb DMvIII from interacting with the EGFRvIII found in the HC2 cells ( Figure 5C ), as compared to the scramble The genes for the anti-EGFRvIII scFvs were cloned into the pBudCE4.1 dicistronic vector. The Ig k-chain signal sequence at the 5' end of each sequence allowed the secretion of the molecule in the culture media. "Knobs-into-holes" configuration and the two cysteine residues at the 3' end of each CH3 domain stabilize the construct. Sequence corresponding to a V5 epitope was cloned at the 3' end of one anti-EGFR scFvs and the other anti-EGFR scFv has Myc as well as a 6xHis tag at 3'end.
epitope control which showed no decrease in detection of EGFRvIII ( Figure 5B ). Additionally, the A431 cells that over express wild type EGFR did not demonstrate any signal with RAb DMvIII ( Figure 5D ), whereas the anti-EGFR antibody recognizes a strong EGFR wild type signal demonstrating that the A431cells retain high expression of the wild type protein ( Figure 5E ). Together these findings indicate again that this recombinant antibody is highly specific towards EGFRvIII.
Immunohistochemistry
Immunohistochemistry ( Figure 6A ). The recombinant antibody RAb CD133 was used as a negative antibody control (Figure 6C ). We extended our findings to two GBM cases, one positive for EGFRvIII (08023) and one negative (04-34497). Consistent with the mouse tumor xenografts, the RAb DMvIII antibody only stained the GBM positive for EGFRvIII and had no cross reactivity to the negative GBM case (Figure 6D &6F) . As a control, we also stained these sections with affinity purified polyclonal anti-EGFRvIII and observed similar results ( Figure 6E and 6G).
Flow cytometry
Because RAb
DMvIII efficiently detects surface EGFRvIII, we asked if it might be an effective reagent for flow cytometry experiments. Under native conditions we observed that RAb DMvIII binds to surface expressed EGFRvIII very efficiently. Figure 7A shows an overlay of plots from HC2 cells stained with increasing concentration of RAb DMvIII (0. One of the earlier concerns in developing the recombinant EGFRvIII antibodies was the potential cross-reactivity towards wt EGFR under conditions where the receptor is over-expressed such as that in A431 cells. Flow cytometry allows quantitation of any potential cross-reaction under native conditions. Figure 7C is A distinct advantage is that recombinantly produced antibodies require no animal for production but otherwise have the properties of conventional antibodies but with additional, improved properties. Indeed, the RAb DMvIII has been engineered to have an IgG Fc region, which confers long serum half life, and has selected to support secondary immune functions, such as antibody dependent cellular cytotoxicity (ADCC) and complement mediated cytotoxicity (CMC) [35, 36] . Studies have demonstrated that Fc-containing BsAb and other fusion proteins do retain the full effector mechanisms of the Fc component [36, 37] .
Effective tumor targeting requires that the antibody should have an affinity for its tumor antigen but extremely high affinity may in fact be detrimental [38] . Previous studies have shown that very high affinity interactions of 10 9 M -1 between antibodies and tumor antigens may actually impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting [39] . Fujimori et al. [40] and Van Osdol et al. [41] have also demonstrated that higher affinity monoclonal antibodies do not homogenously distribute and show less killing of the target cancer cells. According to Robinson et al., a high antibody affinity restricts the localization and tumor penetration of Fv antibody molecules [42] . In another study, Langmuir et al. [26] have shown that a lower affinity mAb of 5.2 × 10 7 M -1 was nearly as toxic as a mAb with an affinity of 1.9 × 10 9 M -1
. Our antibody has an affinity of 1.7 × 10 7 M -1 as shown by saturation ELISA so it could be a reasonable candidate for therapeutic studies.
In separate studies, we have already begun to explore the effectiveness of the RAb DMvIII in targeting tumor spheres derived from glioblastoma tumors. These experiments have already shown that this reagent specifically lyse the cells expressing EGFRvIII and spare normal neural stem cells (Mitra et al., submitted). We performed cytotoxicity assays using a coupled luminescence method on various EGFRvIII transfected cell lines with human NK cells as effectors and found that this reagent significantly induces cell killing of EGFRvIII transfected cells. RAb DMvIII also remarkably reduces the sphere initiating frequency on GBM cells but not in normal cells as it has been shown that EGFRvIII is required for the maintenance of glioma growth in vivo [43] . To further investigate this reagent in mouse models, two GBM sphere lines were incubated with either RAb DMvIII , RAb CD133 or a non-specific human control antibody and orthotopically injected into the cortex of NOD-SCID mice. Tumor formation was analyzed after 26 weeks which revealed a higher incidence of human tumor cells engraftment with RAb CD133 and Hu-IgG1 as compared to RAb DMvIII (Mitra et al., submitted). In order to provide this reagent to other researchers and for future studies, we are planning to scale up antibody production using hollow fiber bioreactor system. Hence this antibody could be of great significance in the field of brain tumor research.
Conclusion
Despite significant advances in the field of neuro-oncology and immunology, there is no widely available EGFRvIII antibody for scientific or clinical use. Furthermore, there is no EGFRvIII antibody clinically proven to be used on patients because of cross reactions and other high risk allergic reactions due to murine Fc portion of the monoclonal antibodies. RAb DMvIII has shown high specificity towards EGFRvIII and thus holds great potential to be further investigated for therapeutic purposes.
Methods
Cell Culture U87-MG, HEK293, A431, and HC2 cell lines were obtained from the American Type Culture Collection (ATCC). U87-MGvIII, a human glioma cell line stably transfected with EGFRvIII, was generously donated by Dr Donald O'Rourke. Cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) (glucose at 4.5 g/L) supplemented with either 10% fetal bovine serum or calf serum as per cell line requirement, 100 units/ml penicillin, 100 μg/ml streptomycin, and 100 μg/ml kanamycin sulfate. The U87-MGvIII cell lines were maintained in Geneticin (G418) selection at 500 μg/mL.
Tumor Sections for Immunohistochemistry
NOD-SCID mice were injected subcutaneously with either 1 × 10 6 U87-MGvIII or A431 cells in the right hind flank of athymic mice. After fourteen days, the mice were sacrificed and the flank tumors were dissected out and fixed in 10% formalin. Four micron tissue sections of both A431 and U87-MGvIII tumors were cut and mounted on the same slide. Cut and mounted primary human glioblastoma tumor sections were obtained from Stanford University brain bank under IRB approved protocols.
Plasmid Construction and Cloning
The pBudCE4:Her2/neu:CD16 bispecific minibody was a kind gift from Dr. Louis Weiner [44] . This construct has an IgG1 CH3 constant domain linked to one single chain variable fragment (scFv) against Her2/neu and one scFv against CD16 in a di-body format on the pBudCE4 vector backbone. The Her2/neu and CD16 variable fragments were replaced with MR1-1 [21] as described below. MR1-1 is a scFv against EGFRvIII selected from a phage display library which was derived from MR1 (scFv), an antibody Fv fragment that recognizes an epitope within the EGFRvIII-specific sequence. The MR1-1 scFv was artificially synthesized based on sequence available from Genbank (accession no. U76382).
The plasmid construct pBudCE4:Her2/neu: CD16 was digested with Not I and Bgl II to remove the Her2/neu scFv. The artificially synthesized MR1-1 was amplified using primers AAGGAAAAAAGCGGCCGCACCAT GGAGACAGACACACTCCTGCTATGGGTACTGCT GCTCTGGGTTCCA GGTTCCACTGGTGGTGACGACTACAAGGAC-GACGATGACAAGCAGGTGAAACTGCAGCAGTCT (scFvEGFRvIII-Not1-ATG/Igk (F)) and GGAAGATC-TACCGCCACTGCCACCTCCGCCTGAACCGCCTC-CACCACTCGAGCCACCTTTGATTTCCAGCTTGG TGC (scFvEGFRvIII-Linker/BglII(R)) and ligated into the scFv Her2/neu position. The resulting recombinant antibody was then digested with Sfil and Xba1 to remove the scFv for CD16. Primers ACATTGGTGCC-GAAACCTATTCACTGCTTACTCGCGGCCCAGCC GGCCCAGGTGAAACTGCAGCAGTCT (scFvLEEKSfil(F)) and GCTCTAGAAC CGCCACTGCCACCTCC GCCTGAACCGCCTCCACCACTCGAGCCACCTTT-GATTTCCAGCTTGGTGC (scFvLEEK-XbI/linker(R)) were used to amplify the second EGFRvIII scFv and ligated into the scFv CD16 position. The plasmid pBudCE4(scfvEGFRvIII) has the CH3 gene with "knobsinto-holes" configuration [45] . Additionally the V5 epitope and His6 tag sequences are cloned at the 3'-end of one anti-EGFRvIII binding arm, whereas the MYC epitope and His6 tag sequences were cloned at the 3'-end of another anti-EGFRvIII binding arm (Figure 1) . A construct with two scFvs against CD133 was created in a similar fashion as a control.
Site Directed Mutagenesis
Site directed mutagenesis was used to change tyrosine H59 of the CDRH2 domain and tyrosine H105 of the CDRH3 domain to phenylalanine for both the anti EGFRvIII scFv sequence inserts (200519-5, Stratagene). Primer CTATTCTCCTTACTCTTTTGCTATGGAC-TACTGGG (F) and primer CCCAGTAGTCCATAG-CAAAAGAGTAAGGAGAATAG (R) were used for the H105 mutation while primer ACTGGCGGT-TATAATACCTTCTATTCAGACAATGTAAAG (F) and primer CTTTACATTGTCTGAATAGAAG-GTATTATAACC GCCAGT (R) were used for the H59 mutation. The resulting mutated vector is called pBudCE4(DMscfvEGFRvIII) and the antibody produced by this construct is called RAb DMvIII whereas the antibody produced by pBudCE4(scfvEGFRvIII) and pBudCE4(scfvCD133) are called RAb vIII and RAb CD133 respectively.
Transfection, Collection and Purification of Antibody
The pBudCE4scfvEGFRvIII, pBudCE4scfvCD133 and pBudCE4DMscfvEGFRvIII plasmids were stably transfected into HEK293 cells using calcium phosphate, and the positive clones were selected using zeocin at 400 μg/ ml. Media was collected from the stably transfected cells and the His-tagged antibodies were isolated and purified using Ni-NTA agarose (R901-15, Invitrogen) according to the manufacturer's recommended protocol. The antibodies were eluted using 500 mM imidazole. The fractions containing the antibodies were identified through Coomassie staining of SDS PAGE. The fractions containing the antibody protein were combined and dialyzed against phosphate buffer solution (PBS). The protein concentration was determined by a Bio-Rad Dc protein assay.
Western Blot Analysis
Confluent HC2 and A431 cells were washed with icecold PBS and lysed using a buffer containing 10 mM Na 2 HPO 4 , 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.2% sodium azide, 0.004% sodium fluoride, 1 mM NaVO 4 , 25 mM β-glycerophosphoric acid, 100 μg of phenylmethanesulfonyl fluoride/ml, 10 μg of aprotinin/ml, and 10 μg of leupeptin/ml (pH 7.35). Cell lysates were centrifuged at 12,000 × g for 10 min at 4°C to clear out cell debris, and protein concentration was determined by Bio-Rad DC protein assay. For gel electrophoresis under non-reducing conditions, forty micrograms of cell lysate was prepared in 6x Laemmli Sample Buffer lacking β-mercaptoethanol and the samples were not boiled. The proteins were resolved on 4-20% Tris-glycine SDS-PAGE gels (Invitrogen) and transferred to nitrocellulose membrane for immunoblot analysis. The membranes were blocked with blocking buffer 5% Blotto (100 mM Tris [pH 7.5], 0.9% NaCl, 0.1% Tween 20 with 5% nonfat dry milk) and incubated with the following antibodies: RAb vIII , RAb DMvIII , mouse anti-actin (MAB1501R, Chemicon), and mouse anti-EGFR (E3138, Sigma Aldrich). Horse radish peroxidase (HRP) affinity pure Donkey anti-Human IgG (709-035-149, Jackson Immunoresearch) was used as the secondary for the recombinant antibodies. Proteins were detected with ECL reagents (#RPN2106V1 and #RPN2106V2, GE Health care).
Immunoprecipitation HC2 (EGFRvIII transfected) and A431 (EGFR wt transfected) cell lysates were isolated as described in the western blot section and 300 μl of lysate was incubated with 12 μg of G100 antibody (formerly commercially available from Zymed lab, now discontinued), RAb CD133 and RAb DMvIII for 1 hr at 4°C. Forty μls of washed 50% slurry of protein Gammabind G Sepharose (17-0885-01, GE Healthcare) was added to each lysate/antibody mix and incubated overnight at 4C. Immunoprecipitates were washed three times with the same lysis buffer and resuspended in sample buffer containing β-mercaptoethanol. Immunocomplexes were resolved on 4-20% Tris-glycine SDS-PAGE gels under normal reducing conditions and transferred to nitrocellulose membranes for immunoblot analysis by mouse anti-EGFR antibody (E3138, Sigma Aldrich).
Immunofluorescence
HC2 and A431 cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X, and blocked with 5% goat serum (0060-01, Southern Biotech). The following antibodies were used for IF: RAb DMvIII , mouse anti-EGFR (EGFR (528): sc-120, Santa Cruz Biotechnology). FITC goat anti-human (A11013, Jackson Immunoresearch) and FITC goat anti-mouse (A11029, Jackson Immunoresearch) were used as secondary antibodies. Images were obtained using a Leica SP2 AOBS Confocal Laser Scanning Microscope. For peptide competition, 20 times higher molar concentration of EGFRvIII peptide (LEEKKGNYVVTDH-C, Genscript) and scrambled peptide (WELKVNGTKDEYH-C, Genscript) was incubated with the primary antibody at 37°C for 1 hour and the mixture was centrifuged at 14000 × g for 5 min. The supernatant was used at the primary antibody incubation step of immunofluorescence protocol.
Immunohistochemistry
Slides were deparaffinized in xylene, and rehydrated in decreasing percentages of ethanol. 3% hydrogen peroxide was used to block endogenous peroxidase and the slides were placed in Diva Decloaker (BioCare Medical) and microwaved for 13 minutes 10 seconds for antigen retrieval. After a cooling down period, the slides were treated with Sniper Universal serum (BioCare Medical) and then incubated with the following antibodies at 0.5 μg/ml overnight at 4°C: Rabbit anti-EGFR antibody, RAb CD133 (recombinant negative control) and RAb DMvIII . Each slide was then incubated with the appropriate secondary and/or tertiary antibody. The secondary antibodies used were: HRP-Anti Rabbit (BioCare Medical), anti-Human IgG rabbit (I9135, Sigma), HRP anti-rabbit antibody (BioCare Medical). Protein expression was detected by betazoid DAB (BioCare Medical). The slides were also counterstained with hematoxylin. Glioblastoma slides were analyzed in a similar fashion to the A431 and U87-MGvIII slides except that the slides for RAb DMvIII were blocked with equal volume of background sniper (BioCare Medical), 5% Blotto and normal human serum (31876, Fisher) and the secondary antibody for RAb DMvIII was rabbit anti-V5 (A00623, Genscript) followed by the tertiary antibody, which was HRP-anti-rabbit (BioCare medical).
Enzyme-Linked Immunosorbent Assay (ELISA)
To determine the affinity constant of the RAb DMvIII a preliminary ELISA was performed to find the concentration of the antibody. This preliminary ELISA was performed with both RAb DMvIII and RAb vIII antibodies to compare the dissociation constant of both the antibodies. A dilution series of antibodies RAb DMvIII and RAb vIII (20 μg/ml-0.01952 μg/ml) in 5% blotto was used. ELISA plates were first coated with 10 μg/ml of EGFRvIII peptide in coating solution in duplicate for each antibody overnight at 4C. The next day the plates were washed with 1× wash buffer (50-63-00, KpL) and 5% blotto was added for 1 hr at RT. Thereafter the respective plates were incubated with different dilutions of RAb DMvIII and RAb vIII ranging from 20 μg/ml to 0.02 μg/ml in 5% blotto for 1 hr at RT. The plates were washed 3 × 10 min each with 1× wash buffer, and then affinity pure Donkey antiHuman IgG (709-035-149, Jackson Immunoresearch) was applied at a 1: 5000 dilution in 5% Blotto for 1 hr at RT, and then the plates were washed 3 × 10 min each. 100 μl of 1× developing reagent was added to each reaction well, and after 10 min., 100 μl of stop solution 1N HCl was added and the absorbance was read at 450 nm. All curves reached a maximum value, which indicated that the reactions proceeded until saturation. The data was plotted as the absorbance at 450 nm versus different antibody concentrations. This gave an equilibrium dissociation constant, K d , for RAb DMvIII of 886 nM and for RAb vIII of 1.7 μM.
Determination of Affinity Constant
Indirect ELISA was performed to determine the affinity constant of the recombinant antibody. This method developed by Friguet et al [33] uses a solid-phase assay for measuring the amount of free antibody present at equilibrium in an antigen-antibody reaction mixture. Since the RAb DMvIII has a lower dissociation constant than RAb vIII as shown by preliminary ELISA we decided to perform indirect ELISA with RAb DMvIII only. Two ninety-six well ELISA plates (353279, BD Falcon) were coated overnight at 4°C with EGFRvIII peptide LEEKKGNYVVTDH-C at a decreasing concentration from 40 ug/ml to 2.5 μg/ml in coating solution (50-84-00, KpL). Wells were then blocked with 5% nonfat dry milk for 1 hr at room temperature. In parallel tubes, antibody at 234 nM is incubated with double the concentration of antigen used in the plates that is (80 μg/ ml-5 μg/ml) in equal volume for final concentration of antibody to be 117 nM (less than the dissociation constant of RAb DMvIII ) and final antigen concentration of (40 μg/ml-2.5 μg/ml) for 30 min at RT, and then the antibody-antigen mixture is transferred to the wells of the first antigen coated microtiter plate and incubated for 15 min. After this incubation, the contents are then transferred to the second antigen coated plate and incubated for another 15 min. The plates were washed with wash buffer (50-63-00, KpL) and secondary donkey antiHuman antibody from Jackson ImmunoResearch was added for 1 hr incubation at RT. After further washes of 3 × 10 min each, 100 μl of substrate (53-00-02, KpL) is applied and 100 μl of stop solution (1 N HCl) is added after 10 min. The absorbance was read at 450 nm in an ELISA plate reader. The data is plotted as the fraction of bound antibody sites versus the ratio of (fraction of bound antibody/concentration of free antigen). The slope gives the value of K, which is the affinity constant.
Flowcytometry
Flowcytometric analysis was performed using RAb DMvIII for native cell surface expressed EGFRvIII. U87-MGwt, U87-MGvIII, A431, and HC2 cell lines were dissociated using TryplE® (Invitrogen, Carlsbad, CA). Cells were resuspended in flow cytometry buffer, consisting of 1× HBSS, pH 7.2, containing 1.55 g/l glucose and 0.1% fraction V of bovine serum albumin (BSA; Sigma-Aldrich, St. Louis,). Cells were counted and diluted to a density of 10 6 cells per milliliter of buffer. 1 μg of RAb DMvIII was used per 10 6 cells unless otherwise specified. Cells were analyzed on a BD LSR-I flowcytometer (BD Biosciences). Unlabeled cells and cells labeled with isotype control (human IgG1) were used to set gating parameters between positive and negative cell populations. Cell aggregates and small debris were excluded from analysis or isolation on the basis of side scatter (measuring cell granularity) and forward scatter (measuring cell size); dead cells were excluded from analysis on the basis of viability dye fluorescence (propidium Iodide). Fluorescent intensities for cells in the population were point-plotted on two-axis graphs or histogram using FlowJo software (Tree Star Inc.).
